The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1211

Completely agree,

To do a canine deal at the moment would be counter productive as we have discussed previously, much better to progress at low cost and allow it to be something extra when negotiating a much larger deal.

My main concern does not relate to the progress of MPL, as I believe the path is well defined and it will continue to shine in any trial. But rather who will now be the face of Pharmaust and sell it to the market ? It's not fair to expect JC to have the time to do that while he is overseeing the daily operations and trials. I'm sure he is capable but 1 person can only do so much.

Cheers